HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Moshe Rehavi Selected Research

Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)

8/2011Platelet vesicular monoamine transporter 2 density in the disruptive behavior disorders.
7/2007Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients.
10/2005Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patients.
9/2005Platelet vesicular monoamine transporter density in untreated patients diagnosed with social phobia.
3/2005Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder.
8/2002Increased platelet vesicular monoamine transporter density in adult schizophrenia patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Moshe Rehavi Research Topics

Disease

8Schizophrenia (Dementia Praecox)
08/2011 - 08/2002
2Neurodegenerative Diseases (Neurodegenerative Disease)
04/2014 - 02/2009
2Mood Disorders (Mood Disorder)
08/2011 - 11/2008
2Phobic Disorders (Phobia)
01/2006 - 09/2005
1Cardiovascular Diseases (Cardiovascular Disease)
01/2012
1Mental Disorders (Mental Disorder)
08/2011
1Autistic Disorder (Autism)
02/2011
1Myocardial Infarction
11/2010
1Tourette Syndrome (Tourette's Syndrome)
07/2007
1Movement Disorders (Movement Disorder)
07/2007
1Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
03/2005
1Anxiety Disorders (Anxiety Disorder)
05/2004
1Infection
10/2003
1Drug Toxicity (Drug Safety)
03/2003
1Major Depressive Disorder (Major Depressive Disorders)
11/2002

Drug/Important Bio-Agent (IBA)

6Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA
08/2011 - 08/2002
4Serotonin (5 Hydroxytryptamine)IBA
11/2010 - 01/2006
4dihydrotetrabenazineIBA
07/2007 - 08/2002
2rasagiline (Azilect)FDA Link
04/2014 - 02/2009
2Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
01/2012 - 01/2006
2Amphetamine (Amfetamine)FDA LinkGeneric
11/2008 - 10/2003
2Dopamine (Intropin)FDA LinkGeneric
07/2007 - 10/2003
2Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
12/2006 - 08/2006
2Antipsychotic Agents (Antipsychotics)IBA
08/2006 - 10/2003
1amsonic acid (DAS)IBA
08/2011
14,4'-dibenzamido-2,2'-stilbenedisulfonic acidIBA
08/2011
1Paroxetine (Paxil)FDA LinkGeneric
02/2011
1Messenger RNA (mRNA)IBA
11/2008
1Clozapine (Clozaril)FDA LinkGeneric
11/2008
1Muscarinic M1 ReceptorIBA
11/2008
1Brain-Derived Neurotrophic Factor (BDNF)IBA
11/2008
1Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA
11/2008
1Haloperidol (Haldol)FDA LinkGeneric
11/2008
1Antidepressive Agents (Antidepressants)IBA
05/2004
1Poly I-CIBA
10/2003
1CytokinesIBA
10/2003
1EnzymesIBA
03/2003

Therapy/Procedure

1Drug Therapy (Chemotherapy)
11/2008